Showing 3631-3640 of 9661 results for "".
- INTerpath-001: Intismeran Plus Pembrolizumab Meets Dual Phase 3 Melanoma Endpointshttps://practicaldermatology.com/news/intismeran-plus-pembrolizumab-meets-dual-phase-3-melanoma-endpoints/2488176/Merck and Moderna reported positive topline results from the phase 3 INTerpath-001 trial evaluating intismeran autogene (V940; mRNA-4157) plus pembrolizumab (Keytruda) as adjuvant therapy for completely resected stage IIB-IV cutaneous melanoma. The individualized mRNA-based neoantigen ther
- Phase 3 Study Shows Sustained Psoriasis Responses With SSGJ-608https://practicaldermatology.com/news/phase-3-study-shows-sustained-psoriasis-responses-with-ssgj-608/2488143/A phase 3 trial of the investigational interleukin (IL)-17A–targeting monoclonal antibody (SSGJ-608) showed high response rates through 52 weeks among adults with moderate-to-severe plaque psoriasis. Investigators for the double-blind, placebo-controlled trial included 458 adults in the sa
- Occupational Exposures Implicated in More Than Half of Chronic Hand Eczema Caseshttps://practicaldermatology.com/news/occupational-exposures-implicated-in-more-than-half-of-chronic-hand-eczema-cases/2488120/A new retrospective study of adults with chronic hand eczema (CHE) found allergic contact dermatitis (ACD) and occupational exposures were common, while most patients improved following diagnosis and treatment recommendations that included allergen avoidance. Investigators evaluated 76 adu
- Monophasic HA Shows Longer-Term Benefit in Nasolabial Fold Correctionhttps://practicaldermatology.com/news/monophasic-ha-shows-longer-term-benefit-in-nasolabial-fold-correction/2488118/A randomized study comparing 2 types of hyaluronic acid (HA) dermal fillers found similar early improvements in moderate-to-severe nasolabial folds (NLFs), with outcomes favoring monophasic HA at 36 weeks. Galinde et al conducted a randomized, controlled, double-blinded, intraindividual st
- D-2570 Shows High PASI Response Rates in Phase 2 Psoriasis Studyhttps://practicaldermatology.com/news/d-2570-shows-high-pasi-response-rates-in-phase-2-psoriasis-study/2488078/A novel oral TYK2 inhibitor produced significantly higher skin clearance rates than placebo in patients with moderate-to-severe plaque psoriasis, according to research published in Journal of the American Academy of Dermatology. D-2570 is a TYK2 inhibitor under development for aut
- Organon Launches Sci-Fi Inspired Campaign to Spotlight VTAMA's First-in-Class Sciencehttps://practicaldermatology.com/news/organon-launches-sci-fi-inspired-campaign-to-spotlight-vtamas-first-in-class-science/2488034/Organon is launching a new multi-channel creative campaign for VTAMA (tapinarof) cream, 1% that draws on science fiction and space-inspired storytelling to engage dermatology clinicians and emphasize the product's novel mechanism of action. Built around the tagline, "It's not science ficti
- Researchers Recommend Refined Trial Design for Pediatric Vitiligo JAK Studieshttps://practicaldermatology.com/news/letter-highlights-trial-design-considerations-in-pediatric-vitiligo/2487858/Correspondence in the Journal of the American Academy of Dermatology asked for caution when interpreting findings from a recent trial evaluating oral Janus kinase (JAK) inhibitors in combination with 308-nm excimer laser th
- Guideline-Based Management Limits Testing and Identifies Risk Factors for Chronic Urticaria in Childrenhttps://practicaldermatology.com/news/guideline-based-management-limits-testing-and-identifies-risk-factors-for-chronic-urticaria-in-children/2487889/Most children presenting with a first episode of acute urticaria (AU) recover with conservative, guideline-based management and require little diagnostic testing, according to a prospective cohort study published in Pediatric Allergy, Immunology, and Pulmonolog
- Text Messaging Intervention Improves Cardiovascular Risk Behaviors in PsO Trialhttps://practicaldermatology.com/news/text-messaging-intervention-improves-cardiovascular-risk-behaviors-in-pso-trial/2487819/A structured text messaging intervention was shown to improve patient activation and several cardiovascular risk behaviors among adults with psoriasis, according to new findings published in JAMA Dermatology.
- CuralysMD Launches Steroid-Free Eczema Lotion Focused on Skin Barrier Supporthttps://practicaldermatology.com/news/curalysmd-launches-steroid-free-eczema-lotion-focused-on-skin-barrier-support/2487770/CuralysMD announced the unveiling of a new over-the-counter eczema skin protectant lotion designed to support skin barrier repair in patients with mild to moderate eczema. The steroid-free formulation contains colloidal oatme